Outbreak of Severe Methemoglobinemia during Maritime Migration (2026)

Peer-Reviewed Study · Bernasconi L, Lonati D, Teresi A, D'Arca F, Ricca N, Merli D, Pes M, Rotolo A, Grignani E, Agozzino C, Benussi CC, Brolli B, Buscaglia E, Carnovale M, Centonze A, Ciotta M, Di Lascio F, Fiorica G, Frigerio T, Genco F, Geraci AM, Ippati G, Mazzarese V, Negrini VM, Palmeri M, Petrolini VM, Petrusa F, Roda E, Scaravaggi G, Schicchi A, Scotto S, Zaffino F, Locatelli CA · September 10, 2026

Bernasconi L et al., 2026-09-10: Italian investigation of 82 migrants with severe methemoglobinemia from dermal absorption of the gasoline additive N-methylaniline; methylene blue was used in 90%, with hemolytic anemia in 38 and two deaths.

Methylene blue therapy was used in 90% of the patients, often in repeated doses.

Bernasconi L et al., 2026-09-10: Italian investigation of 82 migrants with severe methemoglobinemia from dermal absorption of the gasoline additive N-methylaniline; methylene blue was used in 90%, with hemolytic anemia in 38 and two deaths. C3. Study type: coordinated clinical and toxicologic case series/outbreak investigation (Lampedusa and Pavia Poison Control Center, Italy), N=82, March 2024 – December 2025. Median MetHb 44.6% at presentation; 43% at 50% or greater. Methylene blue used in 90%, often repeated doses; delayed hemolytic anemia in 38 patients, frequently transfused; 2 deaths. Toxicologic analysis found N-methylaniline or metabolites in 37 of 39 tested patients and 1.1% N-methylaniline in a fuel sample. Dose not stated in the abstract text captured. Funder/conflicts: not stated in the PubMed record. Published in the New England Journal of Medicine 2026;395:983-991. Study type: uncontrolled series.